Risedronat Sandoz (Risedronate)
Bisphosphonate for the treatment and prevention of osteoporosis
Risedronat Sandoz contains risedronate sodium 35 mg, a bisphosphonate medication taken once weekly for the treatment of osteoporosis. It works by directly strengthening bone tissue and reducing the risk of vertebral and hip fractures in postmenopausal women and men at high fracture risk. This guide covers dosage instructions, side effects, drug interactions, and important safety information based on international clinical guidelines.
Quick Facts
Key Takeaways
- Risedronat Sandoz is a once-weekly bisphosphonate tablet (35 mg) used to treat osteoporosis and reduce the risk of vertebral and hip fractures.
- Take it first thing in the morning on an empty stomach with at least 120 ml of plain water, and remain upright for at least 30 minutes.
- Do not take with food, dairy products, calcium supplements, or antacids, as these significantly reduce absorption.
- Common side effects include digestive discomfort, bone and joint pain, and headache; serious but rare effects include osteonecrosis of the jaw and atypical femoral fractures.
- Treatment duration should be regularly reassessed by your doctor, typically after 3-5 years of continuous use.
What Is Risedronat Sandoz and What Is It Used For?
Risedronat Sandoz belongs to a class of medications known as bisphosphonates, which are the most widely prescribed drugs for the treatment and prevention of osteoporosis worldwide. The active ingredient, risedronate sodium, acts directly on bone tissue by inhibiting osteoclasts — the cells responsible for breaking down bone. By slowing bone resorption, risedronate helps maintain and increase bone mineral density, ultimately strengthening bones and reducing the risk of fractures.
Osteoporosis is a systemic skeletal disease characterised by low bone mass and deterioration of bone microarchitecture, leading to increased bone fragility and susceptibility to fractures. It is particularly common in postmenopausal women due to the decline in oestrogen levels, which normally help protect bone density. According to the World Health Organization (WHO), osteoporosis affects an estimated 200 million people globally, with postmenopausal women being at highest risk. Hip fractures alone are associated with a 20-25% mortality rate within the first year, making effective treatment critically important.
The 35 mg weekly formulation of risedronate was developed to improve patient adherence compared to daily dosing regimens. Clinical trials, including the landmark VERT (Vertebral Efficacy with Risedronate Therapy) studies, have demonstrated that risedronate reduces the incidence of new vertebral fractures by approximately 41-49% over three years and hip fractures by approximately 30% in postmenopausal women with established osteoporosis. These results are consistent across multiple randomised controlled trials and have been confirmed in systematic reviews published by the Cochrane Collaboration.
Risedronat Sandoz is specifically indicated for the treatment of postmenopausal osteoporosis, including severe cases, as well as for the treatment of osteoporosis in men at high risk of fractures. It is also available under other brand names, including Risedronate Bluefish and the original brand Actonel. The medication is manufactured by LEK Pharmaceuticals d.d. (Slovenia) and marketed by Sandoz A/S (Denmark).
Risedronate sodium (the active substance in Risedronat Sandoz) may also be approved for other conditions not covered in this guide. Always follow the instructions of your prescribing doctor and consult them if you have questions about your specific treatment.
What Should You Know Before Taking Risedronat Sandoz?
Contraindications
Risedronat Sandoz should not be taken under the following circumstances:
- Allergy to risedronate sodium or any other ingredient in the formulation (including lactose monohydrate, microcrystalline cellulose, crospovidone, magnesium stearate, hypromellose, macrogol 400, titanium dioxide E171, yellow iron oxide E172, and red iron oxide E172).
- Hypocalcaemia — abnormally low calcium levels in the blood. Calcium levels must be corrected before initiating bisphosphonate therapy.
- Pregnancy — if there is any possibility of being pregnant, if you are currently pregnant, or if you are planning to become pregnant. The safety of risedronate in pregnancy has not been established.
- Breastfeeding — risedronate should not be used during breastfeeding.
- Severe renal impairment — patients with severe kidney problems (creatinine clearance below 30 ml/min) should not use this medication.
Warnings and Precautions
Before starting Risedronat Sandoz, discuss the following conditions with your doctor, as they may require special monitoring or dose adjustments:
Postural requirements: You must be able to sit or stand upright for at least 30 minutes after taking the tablet. If you are unable to maintain an upright position, this medication may not be suitable for you, as lying down can increase the risk of oesophageal irritation and ulceration.
Abnormal bone or mineral metabolism: Conditions such as vitamin D deficiency or abnormal parathyroid hormone levels should be treated before starting risedronate. Both conditions can cause low calcium levels in the body, which may be exacerbated by bisphosphonate therapy. Your doctor may recommend calcium and vitamin D supplementation alongside treatment.
Oesophageal disorders: If you have a history of oesophageal problems, including pain or difficulty swallowing, or if you have been diagnosed with Barrett’s oesophagus (a condition involving cell changes in the lower oesophagus), inform your doctor. Bisphosphonates can cause local irritation of the upper gastrointestinal mucosa, and these pre-existing conditions may increase the risk of oesophageal adverse effects.
Osteonecrosis of the jaw (ONJ): If you have or have previously had pain, swelling, or numbness in your jaw, a feeling of heaviness in the jaw, or tooth loosening, inform your doctor. Additionally, if you are scheduled for dental surgery or tooth extraction, tell your dentist that you are being treated with Risedronat Sandoz. ONJ is a rare but serious condition associated with bisphosphonate use, particularly in patients receiving high-dose intravenous bisphosphonates for cancer treatment. The risk with oral bisphosphonates for osteoporosis is considerably lower but still warrants awareness.
Lactose intolerance: Risedronat Sandoz contains lactose monohydrate. If you have been told by your doctor that you have an intolerance to certain sugars, contact your doctor before taking this medicine. However, the sodium content is minimal — less than 1 mmol (23 mg) per tablet, making it essentially sodium-free.
Children and Adolescents
Risedronat Sandoz is not recommended for use in children and adolescents under 18 years of age due to insufficient data on safety and efficacy in this population. Osteoporosis treatment in paediatric patients requires specialist assessment and alternative approaches.
Pregnancy and Breastfeeding
Risedronat Sandoz is contraindicated during pregnancy and breastfeeding. The potential risks of risedronate exposure to the developing foetus are unknown, and animal studies have shown adverse effects at high doses. Bisphosphonates are incorporated into the bone matrix and may be gradually released over years, meaning that even discontinuation before conception may not completely eliminate foetal exposure.
Women of childbearing potential should use effective contraception during treatment. If pregnancy occurs or is suspected during treatment, the medication should be discontinued immediately and the patient should consult their doctor. Risedronat Sandoz is intended for the treatment of postmenopausal women and men with osteoporosis.
Driving and Operating Machinery
Risedronate has no known effect on the ability to drive or operate machinery. However, as with all medications, you should be aware of how the treatment affects you personally before performing tasks requiring alertness. If you experience dizziness or other adverse effects that could impair your ability, refrain from driving until symptoms resolve.
How Does Risedronat Sandoz Interact with Other Drugs?
Drug interactions with risedronate are primarily related to its absorption in the gastrointestinal tract. Risedronate has very low oral bioavailability (approximately 0.63%), and the presence of divalent and trivalent cations can form insoluble chelate complexes with the drug, reducing absorption even further. Understanding these interactions is essential for maximising the therapeutic benefit of Risedronat Sandoz.
Substances That Reduce Effectiveness
The following substances, if taken at the same time as Risedronat Sandoz, can significantly reduce its absorption and therapeutic effect:
| Interacting Substance | Mechanism | Recommendation |
|---|---|---|
| Calcium supplements | Forms insoluble chelate complexes, preventing risedronate absorption | Take calcium at least 30 minutes after risedronate |
| Magnesium-containing products | Divalent cation chelation reduces bioavailability | Take at least 30 minutes after risedronate |
| Aluminium-containing antacids | Trivalent cation chelation prevents absorption | Take at least 30 minutes after risedronate |
| Iron supplements | Divalent iron ions form complexes with risedronate | Take at least 30 minutes after risedronate |
| Food and beverages (except water) | Food reduces absorption; dairy products (high calcium) particularly problematic | Do not eat or drink anything except plain water for 30 minutes after dosing |
Other Pharmacological Considerations
Risedronate is not metabolised by cytochrome P450 enzymes and does not significantly inhibit or induce these enzymes, meaning clinically significant metabolic drug interactions are unlikely. However, patients taking NSAIDs (non-steroidal anti-inflammatory drugs) or aspirin should be aware that these medications can also cause gastrointestinal irritation, and the combination with bisphosphonates may increase the risk of upper GI adverse effects.
Proton pump inhibitors (PPIs) such as omeprazole, lansoprazole, and pantoprazole are frequently co-prescribed in patients taking bisphosphonates to reduce gastrointestinal side effects. While some studies have suggested that long-term PPI use may reduce calcium absorption and potentially decrease the effectiveness of osteoporosis treatment, the clinical significance of this interaction remains debated. Discuss with your doctor whether PPI use is appropriate for you.
To ensure maximum absorption, establish a consistent morning routine: take your Risedronat Sandoz tablet immediately upon waking with a full glass of plain water (at least 120 ml). Wait at least 30 minutes before taking any other medications, supplements, or having breakfast. This simple timing strategy ensures optimal drug absorption and minimises the risk of interactions.
What Is the Correct Dosage of Risedronat Sandoz?
Adults
Standard Dosage — Postmenopausal Osteoporosis & Male Osteoporosis
Dose: 35 mg (one tablet) once weekly
Day: Choose a convenient day and take the tablet on the same day each week
Time: In the morning, at least 30 minutes before the first food, drink, or other medication of the day
The tablet must be swallowed whole with at least one glass (120 ml or approximately half a standard glass) of plain water. Do not chew, crush, or suck on the tablet, as this may cause oropharyngeal ulceration. You must remain in an upright position (sitting or standing) for at least 30 minutes after taking the tablet to reduce the risk of oesophageal irritation.
| Patient Group | Dose | Frequency | Notes |
|---|---|---|---|
| Postmenopausal women | 35 mg | Once weekly | Including severe osteoporosis; reduces vertebral and hip fracture risk |
| Men with osteoporosis | 35 mg | Once weekly | For men at high risk of fractures |
| Elderly patients | 35 mg | Once weekly | No dose adjustment required |
| Mild-moderate renal impairment | 35 mg | Once weekly | No dose adjustment required |
| Severe renal impairment | Contraindicated | N/A | CrCl < 30 ml/min; do not use |
| Children & adolescents | Not recommended | N/A | Insufficient safety and efficacy data |
Your doctor may also prescribe calcium and vitamin D supplements alongside Risedronat Sandoz, particularly if your dietary intake of these nutrients is insufficient. Adequate calcium and vitamin D are essential for optimal bone health and for bisphosphonate therapy to be maximally effective.
Treatment Duration
The optimal duration of bisphosphonate therapy remains a topic of active research and clinical debate. Current international guidelines, including those from NICE (National Institute for Health and Care Excellence) and the NOF (National Osteoporosis Foundation), recommend reassessing the need for continued treatment after 3-5 years of oral bisphosphonate therapy. Your doctor will consider your fracture risk, bone mineral density results, and response to treatment when making this decision. Do not stop treatment without consulting your doctor, as bone loss may resume after discontinuation.
Missed Dose
If you forget to take your tablet on the scheduled day, take it on the same day you remember. Then continue taking one tablet per week on your usual scheduled day. Do not take two tablets on the same day to make up for a missed dose. If it is almost time for your next scheduled dose, skip the missed dose and resume your regular weekly schedule.
Overdose
If you take more tablets than prescribed, or if a child accidentally ingests the medication, take the following steps immediately:
- Drink a glass of milk — the calcium in milk binds to risedronate and reduces absorption.
- Do not induce vomiting — to reduce the risk of oesophageal injury.
- Contact your doctor, hospital emergency department, or poison control centre immediately for assessment and advice.
- Remain upright — do not lie down, as this increases the risk of oesophageal contact with the drug.
If You Stop Taking Risedronat Sandoz
If you discontinue treatment, your bone mass may begin to decrease over time. The protective effects of risedronate on fracture reduction gradually diminish after stopping the medication. Always discuss any plans to discontinue treatment with your doctor, who can advise on the most appropriate course of action based on your individual circumstances and fracture risk profile.
What Are the Side Effects of Risedronat Sandoz?
Like all medications, Risedronat Sandoz can cause side effects, although not everyone experiences them. The majority of side effects are mild to moderate and typically resolve with continued treatment. However, some side effects are serious and require immediate medical attention. Below is a comprehensive overview of reported side effects organised by frequency.
- Symptoms of a severe allergic reaction: swelling of the face, lips, tongue, or throat; difficulty swallowing or breathing; hives or skin rash
- Severe skin reactions: blistering of skin, mouth, eyes, or mucous membranes (Stevens-Johnson syndrome); widespread red rash with skin peeling (toxic epidermal necrolysis)
- Eye inflammation with pain, redness, and light sensitivity
- Pain when swallowing, difficulty swallowing, chest pain, or new/worsening heartburn
- Bone loss in the jaw with delayed healing or infection, especially after dental procedures
Common Side Effects
- Digestive problems: nausea, abdominal pain, stomach cramps or discomfort
- Constipation, bloating, flatulence (excess gas)
- Diarrhoea
- Bone pain, muscle pain, or joint pain
- Headache
Uncommon Side Effects
- Inflammation or ulceration of the oesophagus causing difficulty swallowing and pain
- Inflammation of the stomach (gastritis) and duodenum (duodenitis)
- Inflammation of the iris (iritis) with redness, eye pain, and visual disturbances
Rare Side Effects
- Tongue inflammation (glossitis) with swelling and possible pain
- Narrowing (stricture) of the oesophagus
- Abnormal liver function test results
- Decreased blood calcium or phosphate levels (usually mild, early in treatment, asymptomatic)
- Atypical femoral fractures (unusual thigh bone fractures), particularly with long-term use
Very Rare & Post-Marketing Reports
- Bone damage in the ear (osteonecrosis of the external auditory canal) — contact your doctor if you have ear pain, discharge, or ear infection
- Hair loss (alopecia)
- Liver disorders, in some cases severe
- Leukocytoclastic vasculitis (red spots on skin caused by inflammation of small blood vessels)
Atypical Femoral Fractures
Atypical (unusual) fractures of the thigh bone (femur) have been reported in patients receiving long-term bisphosphonate therapy for osteoporosis. These fractures are characteristically low-energy fractures that occur in the subtrochanteric or diaphyseal region of the femur. While rare, they are an important safety concern that has led to recommendations for periodic reassessment of the need for continued bisphosphonate treatment.
Contact your doctor if you experience pain, weakness, or discomfort in your thigh, hip, or groin, as these may be early warning signs of an impending atypical femoral fracture. Your doctor may recommend imaging studies to evaluate the integrity of the femoral bone.
Osteonecrosis of the Jaw
Osteonecrosis of the jaw (ONJ) is a rare condition in which bone tissue in the jaw fails to heal after minor trauma such as a tooth extraction, leading to exposed bone, infection, and pain. The risk of ONJ with oral bisphosphonates for osteoporosis is estimated at approximately 1 in 10,000 to 1 in 100,000 patient-years of treatment. Risk factors include dental surgery, poor dental hygiene, corticosteroid use, and cancer therapy. Maintaining good oral hygiene and having regular dental check-ups can help reduce this risk.
It is important to report suspected side effects after the medicine has been authorised. This allows ongoing monitoring of the medicine's benefit-risk balance. Healthcare professionals and patients are encouraged to report any suspected adverse reactions to their national pharmacovigilance authority (e.g., FDA MedWatch in the US, MHRA Yellow Card Scheme in the UK, or the EMA EudraVigilance system in Europe).
How Should You Store Risedronat Sandoz?
Proper storage of medications is essential to maintain their effectiveness and safety. Keep Risedronat Sandoz out of the sight and reach of children at all times. Store the tablets at room temperature — no special storage conditions are required for the blister-packed formulation. However, if the tablets are supplied in high-density polyethylene (HDPE) bottles, they should be used within 6 months of first opening the bottle.
Always check the expiry date before taking any medication. The expiry date refers to the last day of the month printed on the blister pack, label, or carton after “EXP”. Do not use Risedronat Sandoz after this date, as the chemical stability and therefore the effectiveness of the medication may be compromised.
Do not dispose of medications via household waste or down the drain. Return unused or expired medications to your local pharmacy for proper disposal. These measures help protect the environment and prevent accidental exposure to others.
What Does Risedronat Sandoz Contain?
Active Ingredient
Each film-coated tablet contains 35 mg risedronate sodium, which is equivalent to 32.5 mg risedronic acid. Risedronic acid is the pharmacologically active moiety — a nitrogen-containing bisphosphonate that binds with high affinity to hydroxyapatite crystals in bone tissue.
Inactive Ingredients (Excipients)
The following inactive ingredients are present in the tablet formulation:
Tablet core:
- Microcrystalline cellulose — a binder and filler that helps form the tablet structure
- Crospovidone — a disintegrant that helps the tablet break down in the stomach
- Lactose monohydrate — a filler (important for patients with lactose intolerance)
- Magnesium stearate — a lubricant used during tablet manufacturing
Film coating:
- Hypromellose — forms the film coating to improve swallowability
- Macrogol 400 — a plasticiser for the coating
- Titanium dioxide (E171) — a white colouring agent
- Yellow iron oxide (E172) — contributes to the orange colour
- Red iron oxide (E172) — contributes to the orange colour
Appearance and Packaging
Risedronat Sandoz 35 mg tablets are oval-shaped, orange, convex (rounded on both sides) film-coated tablets embossed with “35” on one side. They are available in PVC/aluminium blister packs or HDPE bottles with polyethylene closures. Pack sizes include 1, 2, 4, 10, 12, 16, 28, and 84 tablets, although not all pack sizes may be available in every market.
This medicine contains less than 1 mmol (23 mg) sodium per film-coated tablet, meaning it is essentially sodium-free. This is relevant for patients on sodium-restricted diets.
Frequently Asked Questions About Risedronat Sandoz
Risedronate is available in both daily (5 mg) and weekly (35 mg) formulations. Both provide equivalent therapeutic benefit in treating osteoporosis. The weekly 35 mg tablet was developed to improve patient convenience and adherence, as studies showed that patients were more likely to continue treatment long-term with weekly dosing compared to daily dosing. Risedronat Sandoz is the 35 mg weekly formulation. Your doctor will determine which dosing schedule is most appropriate for your situation.
No. Risedronat Sandoz must be taken only with plain water. Coffee, juice, tea, mineral water, and all other beverages significantly reduce the absorption of risedronate. Even mineral water can contain calcium or magnesium that may interfere with absorption. Take the tablet with at least 120 ml (approximately half a glass) of plain tap water, and wait at least 30 minutes before consuming any other food or beverages.
Staying upright (sitting or standing) for at least 30 minutes after taking Risedronat Sandoz is essential to minimise the risk of oesophageal irritation and ulceration. When you remain upright, gravity helps the tablet pass quickly through the oesophagus and into the stomach. If you lie down, the tablet or its residue may remain in contact with the oesophageal lining, potentially causing irritation, inflammation, or in rare cases, ulceration. This precaution is common to all oral bisphosphonates.
Risedronate begins to reduce bone turnover markers within weeks of starting treatment. However, the clinically meaningful benefit — a reduction in fracture risk — typically becomes evident after 6-12 months of consistent use. Bone mineral density improvements are usually measurable after 12-24 months. It is important to continue taking the medication as prescribed even if you do not feel any immediate effects, as the benefits accumulate over time. Clinical trials have shown sustained fracture risk reduction over treatment periods of up to 7 years.
Inform your dentist that you are taking Risedronat Sandoz (a bisphosphonate) before any dental procedure, especially tooth extractions, implant placement, or jaw surgery. Although the risk of osteonecrosis of the jaw (ONJ) with oral bisphosphonates is very low (estimated at 1 in 10,000 to 1 in 100,000 patient-years), your dentist may wish to take additional precautions. Maintaining good oral hygiene, having regular dental check-ups, and completing necessary dental work before starting bisphosphonate therapy can help minimise risk. Your doctor may advise a temporary treatment break before certain dental procedures, but do not stop the medication without medical guidance.
No, although both are bisphosphonates used to treat osteoporosis. Risedronate (Risedronat Sandoz) and alendronate (Fosamax) are different active substances with slightly different pharmacological profiles. Both are effective at reducing fracture risk, but some studies suggest that risedronate may have a faster onset of action on vertebral fracture reduction and potentially fewer gastrointestinal side effects compared to alendronate. Your doctor will choose the most appropriate medication based on your individual clinical profile and needs.
References
This article is based on the following peer-reviewed sources and international medical guidelines:
- Wells GA, Cranney A, Peterson J, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database of Systematic Reviews. 2008;(1):CD004523. doi:10.1002/14651858.CD004523.pub3
- Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA. 1999;282(14):1344-1352. doi:10.1001/jama.282.14.1344
- McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med. 2001;344(5):333-340. doi:10.1056/NEJM200102013440503
- European Medicines Agency (EMA). Risedronate sodium — Summary of Product Characteristics (SmPC). EMA, 2024.
- National Institute for Health and Care Excellence (NICE). Bisphosphonates for treating osteoporosis. NICE Technology Appraisal Guidance [TA464], updated 2023.
- World Health Organization. WHO Model List of Essential Medicines — 23rd edition. WHO, 2023.
- Adler RA, El-Hajj Fuleihan G, Bauer DC, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016;31(1):16-35.
- Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis. Endocr Pract. 2020;26(Suppl 1):1-46.
- Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30(1):3-23.
- Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29(1):1-23.
Editorial Team
This article has been researched, written, and medically reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians in endocrinology, clinical pharmacology, and internal medicine.
Written by the iMedic Medical Editorial Team based on current international guidelines (EMA, FDA, NICE, WHO) and peer-reviewed clinical evidence.
Independently reviewed by the iMedic Medical Review Board. All facts verified against published systematic reviews and official prescribing information.
All content on iMedic follows evidence-based medical standards (GRADE framework). We maintain complete editorial independence with no pharmaceutical industry funding. Our content undergoes rigorous fact-checking and regular updates to reflect current medical knowledge. Read our full editorial policy.